[Objectives]To analyze the clinical symptoms and epidemiological characteristics of 188 hospitalized pertussis cases in Jingzhou City.[Methods]Clinical data from 188 patients diagnosed with pertussis and admitted to t...[Objectives]To analyze the clinical symptoms and epidemiological characteristics of 188 hospitalized pertussis cases in Jingzhou City.[Methods]Clinical data from 188 patients diagnosed with pertussis and admitted to two tertiary hospitals in Jingzhou City between March and August 2024 were collected.Patients were randomly divided into three groups:<3-year-old,3—17-year-old,and≥18-year-old.A retrospective analysis was performed on their clinical features(including laboratory findings,disease course,and imaging characteristics)and epidemiological characteristics.[Results]In the<3-year-old group,28 cases(36.4%)were unvaccinated and 22 cases(28.6%)had received only one dose of the pertussis vaccine.In the 3—17-year-old group,91 cases(94.8%)had received four doses.Vaccination history was unknown for the≥18-year-old adult group.The<3-year-old group exhibited significantly higher incidences of cough with wheezing/dyspnea,paroxysmal spasmodic cough,cough with cyanosis or facial flushing,wheezes,and moist rales in the lungs compared to both the 3—17-year-old and≥18-year-old groups.Post-tussive vomiting was less frequent in the<3-year-old group than in the 3—17-year-old group but more frequent than in the≥18-year-old group;these differences were statistically significant(P<0.05).The≥18-year-old group had significantly lower incidences of cough with wheezing/dyspnea,paroxysmal spasmodic cough,cough with cyanosis or facial flushing,wheezes,and moist rales in the lungs compared to both the<3-year-old and 3—17-year-old groups(P<0.05).The proportion of cases with pneumonia and increased lung markings was higher in the<3-year-old group than in the 3—17-year-old group but lower than in the≥18-year-old group,showing statistically significant differences(P<0.05).The proportion of cases with pulmonary nodules and fibrotic foci was lower in the<3-year-old group than in both the 3—17-year-old and≥18-year-old groups,and these differences were also statistically significant(P<0.05).The proportion of pneumonia cases in the 3—17-year-old group was lower than in both the<3-year-old and≥18-year-old groups.The proportion of cases with increased lung markings was lower than in the<3-year-old group but higher than in the≥18-year-old group;these differences were statistically significant(P<0.05).The proportion of cases with pulmonary nodules and fibrotic foci in the 3—17-year-old group was higher than in the<3-year-old group but lower than in the≥18-year-old group,with statistically significant differences(P<0.05).The proportion of cases with pulmonary nodules and fibrotic foci was higher in the≥18-year-old group than in both the<3-year-old and 3—17-year-old groups,and these differences were also statistically significant(P<0.05).[Conclusions]Analysis of the clinical symptoms and epidemiological characteristics of 188 hospitalized pertussis cases in Jingzhou City contributes to enhancing the prevention and control of pertussis within the city.展开更多
目的观察恩替卡韦(entecavir,ETV)单用及联合使用聚乙二醇干扰素(peginterferon,Peg-IFN)治疗高病毒载量慢性乙型肝炎(chronic hepatitis B,CHB)患者的疗效。方法该项前瞻性非随机队列研究纳入了2019年12月至2023年12月在南昌大学第一...目的观察恩替卡韦(entecavir,ETV)单用及联合使用聚乙二醇干扰素(peginterferon,Peg-IFN)治疗高病毒载量慢性乙型肝炎(chronic hepatitis B,CHB)患者的疗效。方法该项前瞻性非随机队列研究纳入了2019年12月至2023年12月在南昌大学第一附属医院等4家医院接受治疗的152例高病毒载量CHB患者。根据治疗方案将患者分为ETV组102例及Peg-IFN与ETV联合治疗组50例。主要结局指标为48周时乙型肝炎病毒(hepatitis B virus,HBV)表面抗原(hepatitis B virus s antigens,HBsAg)血清清除率。次要结局指标为48周HBsAg下降水平、HBV e抗原(hepatitis B virus e antigens,HBeAg)血清清除率、HBV-DNA阴转率及下降水平以及ALT下降水平。计量资料符合正态分布,两组间比较采用独立样本t检验,治疗前后组内比较采用重复测量方差分析。计数资料两组间比较采用卡方检验,治疗前后组内比较采用Cochran's Q检验多重比较进行统计分析。结果两组患者的ALT、HBV-DNA和HBsAg水平在整个48周治疗期间较治疗前均显著下降(P<0.001)。治疗48周时,ETV组丙氨酸氨基转移酶(30.82±9.86)U/L显著低于联合治疗组(37.57±19.84)U/L(P=0.027);ETV组HBV-DNA和HBsAg水平分别为(1.22±1.17)lg IU/mL和(3.65±0.85)lg IU/mL均显著高于联合治疗组(0.82±0.96)lg IU/mL和(2.62±1.45)lg IU/mL(P=0.034,P<0.001)。ETV组治疗48周时HBeAg和HBV-DNA清除率较治疗前均显著升高(P<0.001),而HBsAg清除率与治疗前差异无统计学意义(P=0.171)。联合治疗组治疗48周时HBsAg、HBeAg和HBV-DNA清除率较治疗前均显著升高(P<0.05)。治疗48周时,ETV组HBsAg和HBeAg血清清除率分别2.0%和13.7%均显著低于联合治疗组12.0%和38.0%(P=0.027,P=0.001);ETV组HBV-DNA清除率89.2%低于联合治疗组94.0%,差异无统计学意义(P=0.509)。结论Peg-IFN联合ETV治疗方案可作为高病毒载量CHB患者的首选治疗方案。展开更多
文摘[Objectives]To analyze the clinical symptoms and epidemiological characteristics of 188 hospitalized pertussis cases in Jingzhou City.[Methods]Clinical data from 188 patients diagnosed with pertussis and admitted to two tertiary hospitals in Jingzhou City between March and August 2024 were collected.Patients were randomly divided into three groups:<3-year-old,3—17-year-old,and≥18-year-old.A retrospective analysis was performed on their clinical features(including laboratory findings,disease course,and imaging characteristics)and epidemiological characteristics.[Results]In the<3-year-old group,28 cases(36.4%)were unvaccinated and 22 cases(28.6%)had received only one dose of the pertussis vaccine.In the 3—17-year-old group,91 cases(94.8%)had received four doses.Vaccination history was unknown for the≥18-year-old adult group.The<3-year-old group exhibited significantly higher incidences of cough with wheezing/dyspnea,paroxysmal spasmodic cough,cough with cyanosis or facial flushing,wheezes,and moist rales in the lungs compared to both the 3—17-year-old and≥18-year-old groups.Post-tussive vomiting was less frequent in the<3-year-old group than in the 3—17-year-old group but more frequent than in the≥18-year-old group;these differences were statistically significant(P<0.05).The≥18-year-old group had significantly lower incidences of cough with wheezing/dyspnea,paroxysmal spasmodic cough,cough with cyanosis or facial flushing,wheezes,and moist rales in the lungs compared to both the<3-year-old and 3—17-year-old groups(P<0.05).The proportion of cases with pneumonia and increased lung markings was higher in the<3-year-old group than in the 3—17-year-old group but lower than in the≥18-year-old group,showing statistically significant differences(P<0.05).The proportion of cases with pulmonary nodules and fibrotic foci was lower in the<3-year-old group than in both the 3—17-year-old and≥18-year-old groups,and these differences were also statistically significant(P<0.05).The proportion of pneumonia cases in the 3—17-year-old group was lower than in both the<3-year-old and≥18-year-old groups.The proportion of cases with increased lung markings was lower than in the<3-year-old group but higher than in the≥18-year-old group;these differences were statistically significant(P<0.05).The proportion of cases with pulmonary nodules and fibrotic foci in the 3—17-year-old group was higher than in the<3-year-old group but lower than in the≥18-year-old group,with statistically significant differences(P<0.05).The proportion of cases with pulmonary nodules and fibrotic foci was higher in the≥18-year-old group than in both the<3-year-old and 3—17-year-old groups,and these differences were also statistically significant(P<0.05).[Conclusions]Analysis of the clinical symptoms and epidemiological characteristics of 188 hospitalized pertussis cases in Jingzhou City contributes to enhancing the prevention and control of pertussis within the city.
文摘目的观察恩替卡韦(entecavir,ETV)单用及联合使用聚乙二醇干扰素(peginterferon,Peg-IFN)治疗高病毒载量慢性乙型肝炎(chronic hepatitis B,CHB)患者的疗效。方法该项前瞻性非随机队列研究纳入了2019年12月至2023年12月在南昌大学第一附属医院等4家医院接受治疗的152例高病毒载量CHB患者。根据治疗方案将患者分为ETV组102例及Peg-IFN与ETV联合治疗组50例。主要结局指标为48周时乙型肝炎病毒(hepatitis B virus,HBV)表面抗原(hepatitis B virus s antigens,HBsAg)血清清除率。次要结局指标为48周HBsAg下降水平、HBV e抗原(hepatitis B virus e antigens,HBeAg)血清清除率、HBV-DNA阴转率及下降水平以及ALT下降水平。计量资料符合正态分布,两组间比较采用独立样本t检验,治疗前后组内比较采用重复测量方差分析。计数资料两组间比较采用卡方检验,治疗前后组内比较采用Cochran's Q检验多重比较进行统计分析。结果两组患者的ALT、HBV-DNA和HBsAg水平在整个48周治疗期间较治疗前均显著下降(P<0.001)。治疗48周时,ETV组丙氨酸氨基转移酶(30.82±9.86)U/L显著低于联合治疗组(37.57±19.84)U/L(P=0.027);ETV组HBV-DNA和HBsAg水平分别为(1.22±1.17)lg IU/mL和(3.65±0.85)lg IU/mL均显著高于联合治疗组(0.82±0.96)lg IU/mL和(2.62±1.45)lg IU/mL(P=0.034,P<0.001)。ETV组治疗48周时HBeAg和HBV-DNA清除率较治疗前均显著升高(P<0.001),而HBsAg清除率与治疗前差异无统计学意义(P=0.171)。联合治疗组治疗48周时HBsAg、HBeAg和HBV-DNA清除率较治疗前均显著升高(P<0.05)。治疗48周时,ETV组HBsAg和HBeAg血清清除率分别2.0%和13.7%均显著低于联合治疗组12.0%和38.0%(P=0.027,P=0.001);ETV组HBV-DNA清除率89.2%低于联合治疗组94.0%,差异无统计学意义(P=0.509)。结论Peg-IFN联合ETV治疗方案可作为高病毒载量CHB患者的首选治疗方案。
